The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
AADI BIOSCIENCES INC | COM | 00032Q104 | 36,935 | 1,529,402 | SH | SOLE | 1,529,402 | 0 | 0 | ||
ACLARIS THERAPEU | COM | 00461U105 | 1,425 | 98,000 | SH | SOLE | 98,000 | 0 | 0 | ||
ALDEYRA THERAPEUTICS INC | COM | 01438T106 | 2,000 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | ||
ALPINE IMMUNE SCIENCES INC | COM | 02083G100 | 3,186 | 230,000 | SH | SOLE | 230,000 | 0 | 0 | ||
APELLIS PHARMACEUTICALS INC | COM | 03753U106 | 25,295 | 535,000 | SH | SOLE | 535,000 | 0 | 0 | ||
ARROWHEAD PHARMACEUTICALS INC | COM | 04280A100 | 6,995 | 105,500 | SH | SOLE | 105,500 | 0 | 0 | ||
ATHIRA PHARMA INC | COM | 04746L104 | 4,040 | 310,030 | SH | SOLE | 310,030 | 0 | 0 | ||
AVADEL PHARMACEUTICALS PLC | SPONSORED ADR | 999222ZZ8 | 4,686 | 580,000 | SH | SOLE | 580,000 | 0 | 0 | ||
BCLS ACQUISITION CORP- CL A | COM CL A | G0904B105 | 8,263 | 843,122 | SH | SOLE | 843,122 | 0 | 0 | ||
BELLUS HEALTH INC | COM NEW | 07987C204 | 4,226 | 525,000 | SH | SOLE | 525,000 | 0 | 0 | ||
CELLDEX THERAPEUTICS INC | COM NEW | 15117B202 | 13,141 | 340,098 | SH | SOLE | 340,098 | 0 | 0 | ||
CYTEIR THERAPEUTICS INC | COM | 23284P103 | 4,457 | 391,974 | SH | SOLE | 391,974 | 0 | 0 | ||
EYEPOINT PHARMACEUTICALS INC | COM NEW | 30233G209 | 2,975 | 243,072 | SH | SOLE | 243,072 | 0 | 0 | ||
FULCRUM THERAPEUTICS INC | COM | 359616109 | 3,538 | 200,000 | SH | SOLE | 200,000 | 0 | 0 | ||
GH RESEARCH PLC | ORDINARY SHARES | G3855L106 | 9,790 | 419,632 | SH | SOLE | 419,632 | 0 | 0 | ||
GOSSAMER BIO INC | COM | 38341P102 | 1,355 | 119,843 | SH | SOLE | 119,843 | 0 | 0 | ||
GALERA THERAPEUTICS INC | COM | 36338D108 | 1,205 | 262,500 | SH | SOLE | 262,500 | 0 | 0 | ||
HEALTH SCIENCES ACQUISITIONS | ORD SHS | G4411D109 | 3,956 | 392,500 | SH | SOLE | 392,500 | 0 | 0 | ||
IOVANCE BIOTHERAPEUTICS INC | COM | 462260100 | 3,436 | 179,995 | SH | SOLE | 179,995 | 0 | 0 | ||
IVERIC BIO INC | COM | 46583P102 | 7,858 | 470,000 | SH | SOLE | 470,000 | 0 | 0 | ||
JOUNCE THERAPEUTICS INC | COM | 481116101 | 1,065 | 127,500 | SH | SOLE | 127,500 | 0 | 0 | ||
JIYA ACQUISITION CORP -CL A | COM CL A | 47760M102 | 5,496 | 562,500 | SH | SOLE | 562,500 | 0 | 0 | ||
KURA ONCOLOGY INC. COMMON STOCK | COM | 50127T109 | 4,086 | 291,884 | SH | SOLE | 291,884 | 0 | 0 | ||
MIRATI THERAPEUTICS | COM | 60468T105 | 2,934 | 20,000 | SH | SOLE | 20,000 | 0 | 0 | ||
MERUS BV | COM | N5749R100 | 7,489 | 235,500 | SH | SOLE | 235,500 | 0 | 0 | ||
MOLECULAR TEMPLATES INC | COM | 608550109 | 1,264 | 322,500 | SH | SOLE | 322,500 | 0 | 0 | ||
Nuvation Warrants | *W EXP 07/07/202 | 67080N101 | 172 | 90,832 | SH | SOLE | 90,832 | 0 | 0 | ||
PYXIS ONCOLOGY INC SERIES B | COMMON STOCK | 747324101 | 7,435 | 677,753 | SH | SOLE | 677,753 | 0 | 0 | ||
RELMADA THERAPEUTICS INC | COM | 75955J402 | 9,102 | 404,000 | SH | SOLE | 404,000 | 0 | 0 | ||
SEELOS THERAPEUTICS INC | COM | 81577F109 | 4,075 | 2,500,000 | SH | SOLE | 2,500,000 | 0 | 0 | ||
SYNDAX PHARMACEUTICALS INC | COM | 87164F105 | 4,512 | 206,126 | SH | SOLE | 206,126 | 0 | 0 | ||
SIERRA ONCOLOGY INC | COM NEW | 82640U404 | 1,489 | 68,500 | SH | SOLE | 68,500 | 0 | 0 | ||
VIRIDIAN THERAPEUTICS INC | COM | 92790C104 | 6,287 | 318,000 | SH | SOLE | 318,000 | 0 | 0 | ||
VERASTEM INC | COM | 92337C104 | 3,823 | 1,865,000 | SH | SOLE | 1,865,000 | 0 | 0 | ||
VISTAGEN THERAPEUTICS INC | COM NEW | 92840H202 | 22,886 | 11,736,283 | SH | SOLE | 11,736,283 | 0 | 0 | ||
XENON PHARMACEUTICALS INC | COM | 98420N105 | 7,029 | 225,000 | SH | SOLE | 225,000 | 0 | 0 |